Market Currents
Goldman Sachs cuts its price target on NuVasive (NUVA -4.2%) to $14 from $17 and lowers its EPS...
-
Thursday, December 15, 2011, 2:54 PM ETGoldman Sachs cuts its price target on NuVasive (NUVA -4.2%) to $14 from $17 and lowers its EPS outlook to reflect the $37M redemption of convertible debt the medical device company announced earlier this week as well as reduced estimates for the U.S. spine market.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
